Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares (NQ:KNSA)

44.53 -0.14 (-0.30%)
Streaming Delayed Price Updated: 3:16 PM EST, Feb 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Kiniksa Pharmaceuticals International, plc - Class A Ordinary Shares

< Previous 1 2 3 4 Next >
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Combines High Growth Momentum with Strong Technical Setup ↗
Via Chartmill
News headline image
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Fits the High-Growth Momentum and Trend Template Strategy ↗
KNSA stock meets Minervini's Trend Template with strong technicals and high-growth fundamentals, including surging EPS and revenue. 
Via Chartmill
News headline image
Kiniksa (KNSA) Q3 2025 Earnings Call Transcript ↗
Kiniksa (KNSA) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Combines Technical Strength and Fundamental Growth Momentum ↗
KNSA stock shows strong technical momentum per the Minervini Trend Template and impressive fundamental growth with 421% EPS growth. 
Via Chartmill
News headline image
Earnings Scheduled For October 28, 2025 ↗
 
Via Benzinga
News headline image
What to Expect from Kiniksa Pharmaceuticals's Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 29, 2025 ↗
 
Via Benzinga
News headline image
Earnings Preview: Kiniksa Pharmaceuticals ↗
 
Via Benzinga
News headline image
Earnings Scheduled For April 29, 2025 ↗
 
Via Benzinga
News headline image
5 Analysts Have This To Say About Kiniksa Pharmaceuticals ↗
 
Via Benzinga
News headline image
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Identified by High Growth Momentum and Minervini Trend Screen ↗
Kiniksa Pharma (KNSA) is a high-growth momentum stock in a strong technical uptrend, with surging earnings and sales supporting its price advance. 
Via Chartmill
News headline image
What Analysts Are Saying About Kiniksa Pharmaceuticals Stock ↗
4 analysts have expressed a variety of opinions on Kiniksa Pharmaceuticals (NASDAQ: KNSA) over the past quarter, offering a diverse set of opinions from bullish to bearish. 
Via Benzinga
News headline image
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Shows High-Growth Momentum and Strong Technical Setup ↗
Kiniksa Pharmaceuticals (KNSA) shows explosive EPS growth of 483% and strong technicals, trading near 52-week highs in a consolidation pattern that suggests a potential breakout. 
Via Chartmill
News headline image
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Emerges as an Affordable Growth Opportunity ↗
Kiniksa Pharmaceuticals (KNSA) offers strong growth potential at a reasonable valuation. With 125% EPS growth, no debt, and a forward P/E of 21.47, it's a compelling affordable growth stock. 
Via Chartmill
News headline image
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Emerges as a Top Affordable Growth Candidate ↗
Kiniksa Pharma (KNSA) is a strong affordable growth stock with impressive revenue & EPS growth, a reasonable valuation, and a solid debt-free balance sheet. 
Via Chartmill
News headline image
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Exhibits High Growth Momentum and Technical Breakout Potential ↗
Kiniksa Pharma (KNSA) shows strong earnings growth and a bullish technical setup, making it a high-growth momentum stock to watch for a potential breakout. 
Via Chartmill
News headline image
KINIKSA PHARMACEUTICALS INTE (NASDAQ:KNSA): A Strong Growth Stock with a Positive Technical Breakout ↗
Kiniksa Pharma (KNSA) is a strong growth stock with 125% EPS growth, a debt-free balance sheet, and a bullish technical breakout pattern. 
Via Chartmill
News headline image
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) – An Affordable Growth Stock with Strong Fundamentals and Fair Valuation ↗
Affordable Growth investing targets stocks like Kiniksa Pharmaceuticals (KNSA), balancing strong revenue/earnings growth with fair valuations and financial health. KNSA shows high growth (8/10), solid... 
Via Chartmill
News headline image
Kiniksa Pharmaceuticals (NASDAQ:KNSA) Aligns with Minervini’s Trend Model as a Strong Momentum Pick ↗
Kiniksa Pharmaceuticals (KNSA) aligns with Minervini’s Trend Model, showing strong technicals, rapid earnings growth, and upward momentum—ideal for growth investors. 
Via Chartmill
News headline image
Why CommScope Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Gilead Sciences Reports Earnings Thursday. Can The Highly Ranked Drugmaker Beat Its 237% Profit Surge Last Quarter? ↗
The upgraded score means Gilead is now outperforming 96% of all stocks in terms of the most important stock-picking criteria. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth ↗
Via The Motley Fool
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Pony AI, Hims & Hers And Frontdoor Are Among Top 11 Mid-Cap Gainers Last Week (Apr 28-May 2): Are The Others In Your Portfolio? ↗
Top performers last week: PONY, HIMS, ODD, MTSR, CGON, KNSA, KC, FTDR, ATI, PRDO, and IRTC. Have you invested in them? 
Via Benzinga
Topics Artificial Intelligence
News headline image
These stocks are gapping in today's session ↗
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Examining the Future: Kiniksa Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
News headline image
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now ↗
Via The Motley Fool
News headline image
Kiniksa Pharmaceuticals Stock Is Attractive From Valuation Perspective-JP Morgan Analyst ↗
Kiniksa shifts focus to cardiovascular indications, halts abiprubart in Sjögren's, ends its AstraZeneca deal, and advances KPL-387 for recurrent pericarditis. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.